Spinoff Memo Therapeutics boosts Series C Financing, advancing antibody development against BK virus infection

On 7 May, the D-BSSE spinoff Memo Therapeutics announced the extension of its Series C financing, bringing the total amount raised in the funding round to CHF 45 million. According to the media release, the raised capital will be instrumental to expand Phase 2 of clinical development by evaluating the dose of “best-in-class anti-BK Virus antibody”, facilitating “the largest study ever conducted for BK polyomavirus infection in kidney transplantation”.